Ipamorelin vs Sermorelin — two different receptors, often confused
Sermorelin is an analogue of growth-hormone-releasing hormone and acts at the GHRH receptor. Ipamorelin is a growth-hormone secretagogue that acts at the ghrelin receptor instead. They are studied in the same broad area but are not substitutes: they engage different receptors, and the research interest in Ipamorelin has centred on its selectivity relative to earlier secretagogues.
These two are routinely listed side by side as if they were competing versions of the same thing. The comparison is worth making, but not on those terms — the interesting difference is which receptor each one engages, and everything else follows from that.
Two receptors, not one
| Sermorelin | Ipamorelin | |
|---|---|---|
| Class | GHRH analogue | Growth-hormone secretagogue |
| Receptor | GHRH receptor | Ghrelin receptor (GHS-R) |
| Relationship to native signalling | Mimics the hypothalamic releasing hormone | Engages a separate pathway that converges on the same axis |
| Research framing | Studied as a shorter analogue of the native 44-amino-acid hormone | Studied for selectivity relative to earlier secretagogues |
Because the pathways converge downstream, the two get described as interchangeable. Upstream they are not. A compound acting at the ghrelin receptor and one acting at the GHRH receptor are different pharmacological agents that happen to share an area of interest.
What "selective" actually refers to
The selectivity language around Ipamorelin comes from comparisons against earlier secretagogues, which were reported to influence additional hormone axes. Ipamorelin attracted research interest because published characterisation described a narrower profile.
Where the confusion comes from
- Shared vocabulary. Both are described with the phrase "growth hormone", which flattens a real mechanistic distinction.
- Shared category pages. Vendors group them under one heading, including ours, because buyers look for them together.
- Combination research. Ipamorelin is frequently studied alongside a GHRH analogue such as CJC-1295, which reinforces the impression that the two classes are one.
- Regulatory blurring. Tesamorelin is an approved drug; the other two are not. Treating the group as uniform obscures that difference entirely.
The question worth asking instead
"Which is better" presumes a shared endpoint the literature has not established. The answerable question is which receptor a given research model requires, and after that, whether the material you receive is what the label claims. Identity and purity documentation are verifiable. Superiority claims, at this stage of the literature, are not.
The compounds discussed here
Frequently asked questions
- Do Ipamorelin and Sermorelin work the same way?
- No. Sermorelin is a GHRH analogue and acts at the GHRH receptor. Ipamorelin acts at the ghrelin receptor as a growth-hormone secretagogue. Grouping them as one category obscures the fact that they engage entirely different targets.
- Why is Ipamorelin described as selective?
- Earlier growth-hormone secretagogues were reported to affect other hormone axes alongside growth hormone. Ipamorelin drew research attention because published work described a more selective profile. Selectivity is a pharmacological description, not a safety claim.
- How does Tesamorelin fit in?
- Tesamorelin is also a GHRH analogue, so mechanistically it sits with Sermorelin rather than with Ipamorelin. It is a stabilised form and, unlike the other two, exists as an approved prescription drug for a specific indication — which is why it is treated differently in every regulatory context.
References
Primary literature for the compounds above. Links open the record on PubMed.
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Falutz J, et al. J Acquir Immune Defic Syndr. 2010. PMID 20101189 → · summary
- Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV Falutz J, et al. N Engl J Med. 2007. PMID 18057338 → · summary
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog Ionescu M, et al. J Clin Endocrinol Metab. 2006. PMID 17018654 → · summary
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Teichman SL, et al. J Clin Endocrinol Metab. 2006. PMID 16352683 → · summary
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency Prakash A, et al. BioDrugs. 1999. PMID 18031173 → · summary
- Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children Thorner M, et al. J Clin Endocrinol Metab. 1990. PMID 2140733 → · summary
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats Svensson J, et al. Growth Horm IGF Res. 1999. PMID 10373343 → · summary
- Ipamorelin, the first selective growth hormone secretagogue Raun K, et al. Eur J Endocrinol. 1998. PMID 9849822 → · summary